Pro-CRISPR PcrIIC1-associated Cas9 system for enhanced bacterial immunity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Potential role of a CRISPR-Cas-activated toxin-antitoxin system in bacterial immunity.Nature communications · 2026
   Article
2. A practical guide for characterization of novel CRISPR-Cas systems with Pro-CRISPR factors.Biophysics reports · 2026
   Article
3. Phage-associated Cas12p nucleases require binding to bacterial thioredoxin for activation and cleavage of target DNA.Nature microbiology · 2026
   Article
4. Anti-CRISPR protein AcrIIA5 can enhance the activity and security of prime editing.Nature communications · 2025
   Article
5. An updated evolutionary classification of CRISPR-Cas systems including rare variants.Nature microbiology · 2025
   Article
6. Animals : an open access journal from MDPI · 2025
   Review
7. Improving adenine base editing precision by enlarging the recognition domain of CRISPR-Cas9.Nature communications · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

22 authors.

Funding

Abstract

Indexed as